Equity Sector Funds Very High Risk Fund Managers: Anandha Padmanabhan Anjeneyan, Utsav Mehta, Sharma Vivek, Puneet Pal
Equity Sector Funds Very High Risk
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -5.29% | -5.11% | -2.87% | -5.2% | 5.62% | 0% | 0% | 0% | 0% | 0% | -3.92% |
| Category returns | -3.47% | -5.71% | -4.62% | -5.85% | 5.92% | 8.03% | 21.45% | 13.48% | 13.49% | 12.42% | N/A |
| Absolute returns | -4.3% | -2.74% | -1.94% | -4.01% | 5.62% | 0% | 0% | 0% | 0% | 0% | -4.2% |
| Rank within category | 18 | 8 | 4 | 8 | 10 | 15 | 11 | 11 | 10 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -2.67% | -2.64% |
| Q1 returns | N/A | -7.32% | -2.64% |
| Q2 returns | N/A | 5.55% | 0% |
| Q3 Returns | N/A | -3.44% | N/A |
| Q4 Returns | N/A | 3.04% | N/A |
Expense ratio: 2.37%
Inclusive of GST
Exit load
0.50% on or before 90D, Nil after 90D
| Alpha | -0.308542 |
| Beta | 0.5694 |
| Sharpe Ratio | -0.1703 |
| Sortino Ratio | -0.283864 |
| R-Squared | 0.3283 |
| Tracking Error | 3.3792 |
| Downside Risk | 14.3917 |
| Std. Deviation (Annualised) | 12.6334 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | -2.08% | -6.51% | -5.9% | -6.51% | 6.26% | 25.06% | 15.7% | 0% | 18.48% | 6,801.16 | 1.86 | 0.40 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -4.11% | -4.62% | -3.79% | -5.93% | 6.07% | 23.64% | 15.51% | 11.7% | 16.02% | 4,063.64 | 1.93 | 0.38 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -1.88% | -3.69% | -4.73% | -4.46% | 6.78% | 23.55% | 13.92% | 12.25% | 14.43% | 1,055.53 | 2.28 | 0.36 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -3.41% | -2.85% | -1.56% | -1.97% | 8.48% | 22.6% | 14.07% | 0% | 18.64% | 2,843.74 | 1.93 | 0.35 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -3.32% | -5.25% | -3.26% | -3.45% | 6.08% | 21.77% | 12.51% | 0% | 17.65% | 854.04 | 2.30 | 0.35 | Very High |
| Nippon India Pharma Fund - Growth | -4.62% | -6.46% | -3.77% | -6.73% | 5.1% | 20.97% | 13.46% | 14.03% | 19.46% | 8,306.35 | 1.81 | 0.34 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -5.22% | -8.55% | -7.53% | -8.14% | 2.86% | 20.46% | 13.16% | 11.71% | 10.6% | 1,229.42 | 2.11 | 0.32 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -2.39% | -9.82% | -7.37% | -8.87% | 3.11% | 19.42% | 12.81% | 0% | 19.09% | 3,033.42 | 1.94 | 0.31 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -4.7% | -8.97% | -8.22% | -7.24% | 0.63% | 19.02% | 10.25% | 0% | 15.1% | 78.30 | 2.36 | 0.30 | Very High |
| PGIM India Healthcare Fund - Regular Plan - Growth Current | -5.29% | -5.11% | -2.87% | -5.2% | 5.62% | 0% | 0% | 0% | -3.92% | 85.19 | 2.37 | -0.17 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 97.20% |
| Cash & Cash Equivalents and Net Assets | 2.80% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 65.00% | |
| Healthcare Services | 25.31% | |
| Others | 2.80% | |
| Chemicals & Petrochemicals | 3.00% | |
| Financial Technology (Fintech) | 1.29% | |
| Insurance | 1.23% | |
| Retailing | 0.79% | |
| IT - Services | 0.58% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 12.41% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.01% |
| Aster DM Healthcare Ltd. | Healthcare Services | Domestic Equities | 7.51% |
| JB Chemicals & Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.98% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 5.56% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.44% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.02% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.96% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.94% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.81% |
| Clearing Corporation of India Ltd. | Cash & Cash Equivalents and Net Assets | 3.56% | |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.16% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 3.00% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 2.99% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.85% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.48% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 2.25% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.12% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.64% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.60% |
| PB Fintech Ltd. | Financial Technology (Fintech) | Domestic Equities | 1.29% |
| ICICI Lombard General Insurance Company Ltd. | Insurance | Domestic Equities | 1.23% |
| Dr. Agarwal's Health Care Ltd. | Healthcare Services | Domestic Equities | 1.00% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.94% |
| Lenskart Solutions Ltd. | Retailing | Domestic Equities | 0.79% |
| Orchid Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.58% |
| Sagility Ltd. | IT - Services | Domestic Equities | 0.58% |
| Dr Agarwals Eye Hospital Ltd. | Healthcare Services | Domestic Equities | 0.55% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -0.76% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 5.62%
3-year: 0%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹9.58 (approx.) for the PGIM India Healthcare Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹85 Cr.
The expense ratio for the Regular Plan is 2.37.
0.50% on or before 90D, Nil after 90D.
Minimum SIP starts at ₹1000.
The minimum lump sum investment is ₹5000. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund managers: Anandha Padmanabhan Anjeneyan, Utsav Mehta, Sharma Vivek, Puneet Pal
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
